Skip to main content
. Author manuscript; available in PMC: 2016 Oct 15.
Published in final edited form as: J Immunol. 2015 Sep 4;195(8):3537–3545. doi: 10.4049/jimmunol.1500905

Figure 6.

Figure 6

Effect of anti-IL-33 and ST2 blockade on pulmonary responses to direct challenges with LTE4. The indicated groups were treated single intraperitoneal doses of rat anti-mouse IL-33, IgG isotype control, recombinant ST2-Fc fusion protein, or Fc control 24 h before the challenge with LTE4. A. Peak percent changes in RL from baseline are displayed. B. BAL fluid content of histamine, mMCP-1, and PGD2. C. Effects of CysLT1R blockade or TP receptor antagonism on LTE4-induced changes in RL The indicated groups received Montelukast P.O. in drinking water beginning 24 h before challenge, or received a single intraperitoneal dose of the selective TP receptor antagonist SQ29,548. * p<0.05, ** p<0.01, *** p<0.001.